Physician profile
Michael Rotman
NPI 1649284100
$18,029.38
in general payments reported to CMS, 2019-2025
40 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,961 · 2020: $994 · 2021: $1,704 · 2022: $7,304 · 2023: $1,328 · 2024: $1,381 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425 · Education: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.56 |
| Education | $641.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $5,972.35 | 2020-2022 | |
| Aytu Biopharma, INC. | $3,198.00 | 2019-2020 | |
| Astellas Pharma US INC | $1,556.08 | 2019-2025 | Myrbetriq, Xtandi |
| Teleflex LLC | $1,304.48 | 2021-2025 | Urolift |
| Janssen Biotech, INC. | $1,203.14 | 2019-2025 | Erleada, Akeega |
| Neotract INC. | $597.40 | 2019-2020 | |
| Antares Pharma, INC. | $582.33 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Axonics, INC. | $436.80 | 2023-2024 | Bulkamid, Axonics |
| Pfizer INC. | $407.97 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $345.32 | 2020-2025 | Prolaris |
| Tolmar, INC. | $235.77 | 2023-2025 | Jatenzo |
| Ferring Pharmaceuticals INC. | $221.85 | 2019-2025 | Adstiladrin |
| Urogen Pharma, INC. | $182.60 | 2022-2025 | |
| Dentsply Ih Ab | $161.05 | 2023-2025 | Lofric, Lofric |
| Abbvie INC. | $152.18 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rotman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.